US 12,257,293 B2
Methods of treatment for cervical dystonia
Curtis L. Ruegg, Redwood City, CA (US); and Jacob M. Waugh, Palo Alto, CA (US)
Assigned to REVANCE THERAPEUTICS, INC., Newark, CA (US)
Filed by REVANCE THERAPEUTICS, INC., Newark, CA (US)
Filed on Dec. 9, 2021, as Appl. No. 17/547,211.
Application 17/547,211 is a continuation of application No. 16/614,773, abandoned, previously published as PCT/US2018/033397, filed on May 18, 2018.
Claims priority of provisional application 62/508,324, filed on May 18, 2017.
Prior Publication US 2022/0096610 A1, Mar. 31, 2022
Int. Cl. A61K 38/48 (2006.01); A61K 9/00 (2006.01); A61K 47/26 (2006.01); A61K 47/42 (2017.01); A61P 21/00 (2006.01)
CPC A61K 38/4893 (2013.01) [A61K 47/26 (2013.01); A61K 47/42 (2013.01); A61P 21/00 (2018.01); A61K 9/0019 (2013.01)] 9 Claims
 
1. A method of treating cervical dystonia in an individual in need of treatment, the method comprising:
administering by a plurality of injections a first treatment dose of a sterile injectable composition into a plurality of the muscles in the affected area in the individual in need of treatment to achieve a therapeutic effect following the first treatment;
wherein the composition comprises a pharmaceutically acceptable diluent suitable for injection;
a botulinum toxin component is botulinum toxin of serotype A having a molecular weight of 150 kDa; and
a positively charged carrier component having the amino acid sequence RKKRRQRRRG-(K)15-GRKKRRQRRR (SEQ ID NO: 4);
wherein the total first treatment dose of botulinum toxin component administered to the individual is 100 U to 300 U;
wherein the positively charged carrier is non-covalently associated with the botulinum toxin component; and
wherein the first treatment of the composition administered by the plurality of injections to the individual achieves a therapeutic effect of at least about 24 weeks, before a second or subsequent treatment with botulinum toxin is administered.